Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study

Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study

PRIMARY OBJECTIVE:
I. To show that endoscopic ultrasound (EUS)-guided photodynamic therapy (PDT) to the pancreas is effective at direct ablation of advanced or locally advanced and small volume metastatic pancreatic tumors in a multicenter setting.
SECONDARY OBJECTIVE:
I. To evaluate the predictability of tumor necrosis as a function of delivered energy, based on pre-PDT contrast computed tomography (CT) scans.
TERTIARY OBJECTIVE:
I. Evaluate the safety of chemotherapy given two days after PDT.
QUARTERNARY OBJECTIVE:
I. Demonstrate that cancer biomarkers in pre- versus (vs.) post-PDT are surrogate markers of response.
OUTLINE:
Patients receive verteporfin intravenously (IV) and after 60 minutes undergo EUS-guided PDT.
After completion of study treatment, patients are followed up at 14 days, and at 3, 6, and 12 months.

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 15, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments